Yazar "Yeksan M." seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Association of fetuin - A levels with carotid intima media thickness and valvular calcification in hemodialysis and peritoneal dialysis patients(2013) Solak Y.; Inal A.; Atalay H.; Kayrak M.; Biyik Z.; Türkmen K.; Yeksan M.Background: Fetuin-A is a negative acute-phase reactant which prevents vascular calcification. Coronary artery disease (CAD) is the most important cause of mortality in patients undergoing renal replacement therapy (RRT). The key element of cardiovascular disease (CVD) seen in end-stage renal disease patients who are on dialysis treatment is accelerated calcific atherosclerosis. There are a limited number of studies in which HD and PD is compared in terms of fetuin-A level. OBJECTIVE: We aimed to investigate the association of serum fetuin-A level with valvular calcification and predictors of CAD in hemodialysis (HD) and peritoneal dialysis (PD) patients. MATERIAL and METHODS: 39 HD (24 males, 15 females) and 39 PD (25 males, 14 females) patients were included in the study. We determined carotid artery intima media thickness (CIMT) and evaluated heart valve calcification via echocardiography. We also measured serum fetuin-A level, CRP, ferritin, fibrinogen and serum albumin level. According to fetuin-A level, patients were stratified into quartiles. RESULTS: Fetuin-A level was significantly lower in HD patients when compared with that of PD patients (28.6±5.934 ng/ml, 32±4.8 ng/ml respectively p<0.001). There was a significant negative correlation between CIMT and fetuin-A level. CIMT was found to be lower in PD patients than in HD patients. We found a positive correlation between fetuin-A and dialysis adequacy and albumin level. There was a negative correlation of fetuin-A with age, fibrinogen, ferritin and CRP. Fetuin-A level was lower in patients with aortic calcification. Conclusion: Fetuin-A level was found to be lower in HD patients. Fetuin-A may be a novel marker for CVD in patients undergoing RRT.Öğe Hemodynamic changes with Recombinant Human Erythropoietin (r-HuEPO) therapy in uremic hemodialyzed patients(1994) Yeksan M.; Tamer N.; Turk S.; Cirit M.; Telli H.H.; Bayram A.; Erdogan Y.The aim of this study was to evaluate the effect of Recombinant Human Erythropoietin (r-HuEPO) treatment on echocardiographic parameters, plasma renin activity (PRA), plasma aldosterone and plasma atrial natriuretic peptide (ANP) levels in uremic hemodialysis patients. Over a period of 4 months, we administered r-HuEPO at a dose of 60 U/kg, three times a week after dialysis to 21 patients on chronic maintenance hemodialysis. Sixteen uremic patients were taken as control group. M-mode echocardiography was carried out by the same specialized examiner. Heart rate and blood pressure were recorded at the same time. Students-t test was used for statistical analysis. The mean values of diastolic blood pressure increased. There were no changes in heart rates. In the measurements of M-mode echocardiography, left ventricular internal dimensions during systole and diastole decreased but there were no significant changes in intraventricular septal and left ventricular posterior wall thickness. While the ejection fraction did not change, stroke volume and cardiac output decreased respectively. PRA and aldosterone levels significantly decreased. ANP levels increased. No hemodynamic parameter change was seen in the control group. Probably, the increase in whole blood viscosity associatad with the increase in peripheral resistance was responsible for those hemodynamic alterations caused by r-HuEPO therapy.Öğe İmportance of Pericardium Drainage in Purulent and Tuberculosis Pericarditises(1989) Solak H.; Yüksek T.; Yeniterzi M.; Yeksan M.; Çalışkan U.; Yılmaz O.; Ecirli S.[Abstract not Available]Öğe Utility of double filtration plasmapheresis in acute antibody mediated renal allograft rejection: Report of three cases(2011) Solak Y.; Atalay H.; Polat I.; Anil M.; Türkmen K.; Biyik Z.; Yeksan M.Plasmapheresis is an extracorporeal procedure, which is often employed to rapidly lower circulating titers of autoantibodies, immune complexes or toxins. There are two types of plasmapheresis namely, regular plasmapheresis (RPP) by centrifugation and membrane filtration, and double filtration plasmapheresis (DFPP) which is a special form of membrane filtration in which two membranes called as plasma separator and plasma fractionator are employed to filter macromolecules more selectively. DFPP have several advantages over RP. Despite widespread utilization of DFPP in the setting of ABO blood group incompatible kidney transplantation, there is no report regarding DFPP in patients with antibody mediated acute renal allograft rejection who are good candidates for beneficial effects of DFPP. Here we report three renal transplant recipients in whom DFPP was applied as a component of anti-rejection treatment regimen.
